Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
The FDA has notified healthcare professionals of reports of clinically significant liver injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, occurring as early as six…
John Goodman, president of J O Goodman & Associates, Inc. – Heart And Vascular Business Consultants, discusses the role of politics in healthcare. jogoodmanassociates.comRelated Videos on The Doctor’s…
A new study indicates that a single course of rituximab reduces inflammatory brain lesions and clinical relapses for as long as 48 weeks in patients with relapsing-remitting multiple…
The FDA has issued an update to inform the public that Baxter Healthcare Corporation has extended its recall of multi-dose vials of heparin sodium for injection to also…
Wissam Chatila, MD, Associate Professor of Medicine, Temple University School of Medicine, discusses obstructive sleep apnea and the importance of education for those who suffer from this. References…
The FDA has approved natalizumab (Tysabri) for the treatment of moderate-to-severe Crohn’s disease in patients with evidence of inflammation who have had an inadequate response to, or are…
The CDC’s FluView, a weekly influenza surveillance report prepared by the influenza division, posts the statistics for influenza week 6, February 3 – February 9, 2008. References and…
Gilbert E. D’Alonzo, MD, Professor of Medicine, Temple University School of Medicine, discusses heparin prophylaxis. References and Resources Chibbaro S, Tacconi L. Safety of deep venous thrombosis prophylaxis…
Steven G. Kelsen, MD, FACP, FCCP, Professor of Medicine, Microbiology, and Immunology, Temple University School of Medicine, discusses how one can try to alleviate household allergens. References and…
Impax Laboratories Inc. received a nonapprovable letter from the FDA regarding its New Drug Application and subsequent submissions for carbidopa/levodopa extended-release tablets. The FDA’s decision was primarily based…
